- Home
- FFA vs TECX Comparison
FFA vs TECX Comparison
Compare FFA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- TECX
- Stock Information
- Founded
- FFA 2004
- TECX 2019
- Country
- FFA United States
- TECX United States
- Employees
- FFA N/A
- TECX N/A
- Industry
- FFA Investment Managers
- TECX
- Sector
- FFA Finance
- TECX
- Exchange
- FFA Nasdaq
- TECX Nasdaq
- Market Cap
- FFA 416.1M
- TECX 387.1M
- IPO Year
- FFA N/A
- TECX 2018
- Fundamental
- Price
- FFA $21.71
- TECX $16.60
- Analyst Decision
- FFA
- TECX Buy
- Analyst Count
- FFA 0
- TECX 6
- Target Price
- FFA N/A
- TECX $79.17
- AVG Volume (30 Days)
- FFA 26.1K
- TECX 678.8K
- Earning Date
- FFA 01-01-0001
- TECX 11-07-2025
- Dividend Yield
- FFA 6.72%
- TECX N/A
- EPS Growth
- FFA N/A
- TECX N/A
- EPS
- FFA N/A
- TECX N/A
- Revenue
- FFA N/A
- TECX N/A
- Revenue This Year
- FFA N/A
- TECX N/A
- Revenue Next Year
- FFA N/A
- TECX N/A
- P/E Ratio
- FFA N/A
- TECX N/A
- Revenue Growth
- FFA N/A
- TECX N/A
- 52 Week Low
- FFA $15.84
- TECX $13.70
- 52 Week High
- FFA $19.30
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- FFA 54.22
- TECX 45.54
- Support Level
- FFA $21.28
- TECX $17.45
- Resistance Level
- FFA $22.00
- TECX $26.00
- Average True Range (ATR)
- FFA 0.16
- TECX 2.05
- MACD
- FFA 0.02
- TECX -0.01
- Stochastic Oscillator
- FFA 59.64
- TECX 2.02
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.